| 7:30 AM |
Registration/Continental Breakfast/Exhibits
|
| 8:25 AM |
Welcome and Introductions
Hubert Fernandez
|
Moderator: Diego Torres-Russotto
|
| 8:30 AM |
Hope vs. Hype I: It is time to redefine and rename Parkinson disease based on alpha synuclein
- Agree: Kathleen Poston
- Disagree: Tiago Mestre
|
| 9:30 AM |
Convention vs. Innovation I: Skin biopsy for synuclein inclusions should now be used in the clinical setting
- Agree: Drew Kern
- Disagree: Liana Rosenthal
|
| 10:30 AM |
Refreshment Break/Exhibits
|
| 11:00 AM |
Convention vs. Innovation II: Genetic profiles should be a standard consideration in the assessment for DBS candidacy
- Agree: Thomas Tropea
- Disagree: Adolfo Ramirez-Zamora
|
| 12:00 PM |
Lunch/Exhibits
|
Moderator: Irene Malaty
|
| 1:00 PM |
Convention vs. Innovation III: The promise of stem cell therapy in Parkinson disease remains bright and getting brighter
- Agree: Claire Henchcliffe
- Disagree: Alfonso Fasano
|
| 2:00 PM |
Hope vs. Hype II: We should stop embarking on epidemiology-based disease-modifying clinical trials
- Agree: Alberto Espay
- Disagree: Michael Schwarzschild
|
| 3:00 PM |
Refreshment Break/Exhibits
|
| 3:30 PM |
Hope vs. Hype III: We should be more open to endorsing cannabis for Parkinson disease
- Agree: Eric Farbman
- Disagree: Diego Torres-Russotto
|
| 4:30 PM |
Preview on the Updates Session: The State of Genetics in PD
Martha Nance
|
| 5:15 PM |
Adjourn
|
| 5:15–6:30 PM |
Welcome and Networking Reception
|
